Dr. Ara D. Metjian, MD

Dr. Metjian practices at Duke University Hospital in Durham, North Carolina, part of Duke University.

Dr. Metjian's NPI, 1679635502, was assigned on December 15, 2006. Dr. Metjian holds Colorado license DR.64577.

Dr. Metjian's primary practice is Duke University Hospital, at 2301 Erwin Rd, Durham, NC 27705 in Durham County. The practice phone is (919) 684-8111.

Dr. Metjian's primary practice is Duke University Hospital in Durham, North Carolina, part of Duke University. Dr. Metjian is also affiliated with Duke Regional Hospital. The medical group on file is Duke Health Integrated Practice. Dmand AI also links Dr. Metjian to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Metjian practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Metjian's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Metjian's licenses on file in 2 states: Colorado and North Carolina.

CMS data shows 61 Medicare services from Dr. Metjian across 3 procedure codes in 2024, for 71 Medicare patients. Medicare paid $5,993 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 71 Medicare patients who saw Dr. Metjian in 2024. The largest group is 65 to 74, with 27 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Metjian's median patient age at 64, with 62% women.

In 2024, Dr. Metjian wrote 80 Medicare Part D claims for 26 patients. 34% of them were for generic drugs. CMS names the drug for 58 of them, across 3 drugs with 11 or more claims each, at $47,841 in total drug cost. In 2023, CMS named 50 claims across 3 drugs.

Dr. Metjian accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Metjian as offering telehealth.

Dmand AI links 22 papers to Dr. Metjian, published from 2015 to 2024. 2019 was the busiest year, with 3. The most frequent topics are Purpura, Thrombotic Thrombocytopenic, Plasma Exchange and ADAMTS13 Protein. Dr. Metjian has published most often in Blood Adv. Dr. Metjian's most frequent co-authors are Spero R. Cataland, MD, Shruti Chaturvedi, MD and Ana Gabriela Antun, MD.

Dmand AI links Dr. Metjian to 7 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Purpura, Thrombotic Thrombocytopenic, Thrombophilia and Antiphospholipid Syndrome. Open Payments lists research payments to Dr. Metjian that name 2 trials.

CMS Open Payments shows 123 general payments to Dr. Metjian from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Sanofi and Genzyme US Companies paid the most, $59,563. It also lists 19 research payments totaling $9,319 from 2019 to 2022, naming 2 clinical trials.